What is the pathophysiology of a left atrial myxoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Left Atrial Myxoma

Left atrial myxoma causes clinical manifestations through three distinct pathophysiologic mechanisms: mechanical obstruction of mitral valve blood flow during diastole, systemic embolization of tumor fragments or surface thrombus, and constitutional symptoms from cytokine release. 1

Anatomic Origin and Tumor Characteristics

  • Left atrial myxomas arise predominantly from the interatrial septum at the fossa ovalis region, which explains their typical attachment site and influences surgical approach. 1

  • The tumor consists of myxoma cells (lepidic cells) that are polygonal to stellate-shaped with eosinophilic cytoplasm, embedded in abundant myxoid matrix rich in mucopolysaccharides. 1

  • Vascular channels of varying caliber are scattered throughout the tumor, with endothelial cells lining these channels; hemorrhage and hemosiderin deposits are common, especially in larger tumors. 1

  • Surface architecture varies from smooth (65% of cases) to friable or villous (35% of cases), with the villous morphology conferring markedly higher embolic potential. 1, 2

Mechanism 1: Mechanical Obstruction

  • Myxomas cause dynamic obstruction of the mitral valve orifice during diastolic filling, reducing left ventricular filling and cardiac output. 1

  • Prolapsing tumors (Type I) move from the left atrium into the left ventricle in early diastole and back into the atrium in early systole, creating prominent c and v waves with rapid y descent on left atrial pressure tracings. 3

  • Nonprolapsing tumors (Type II) remain in the left atrium throughout the cardiac cycle, impeding mitral valve flow continuously and producing a slow y descent indistinguishable from mitral stenosis. 3

  • This mechanical obstruction leads to syncope from transient reduction in cardiac output and cerebral hypoperfusion, particularly when the tumor intermittently obstructs the valve. 1

  • Larger tumors correlate with more severe cardiac symptoms, pseudo-mitral auscultation findings (present in 53.5% of patients), and electrocardiographic or radiologic signs of left atrial hypertrophy. 2

Mechanism 2: Embolic Complications

  • The overall embolism rate with cardiac myxomas is 25%, with embolic stroke being the presenting symptom in up to 50% of cases. 1, 4

  • Embolic events result from two sources: thrombus formation on the tumor surface or direct embolization of tumor fragments. 1, 4

  • Villous or papillary surface architecture dramatically increases embolic risk because the friable surface generates thrombus and sheds tumor fragments more readily than smooth-surfaced tumors. 1, 2

  • Males have statistically greater risk than females of developing embolic complications, though the mechanism for this sex difference is not fully elucidated. 2

  • Embolic phenomena can cause stroke, peripheral arterial occlusion, coronary artery occlusion leading to myocardial infarction, and formation of myxomatous intracranial aneurysms (present in up to 50% of myxoma-related embolic strokes). 5, 6

  • Paradoxical embolism can occur in patients with right-sided tumors and patent foramen ovale, allowing venous thrombus or tumor fragments to reach the systemic circulation. 4, 5

Mechanism 3: Constitutional Symptoms

  • Constitutional symptoms occur in 34% of patients and include fever, weight loss, and symptoms resembling connective tissue disease. 2

  • These systemic manifestations are mediated by cytokine release, particularly interleukin-6, from the tumor. 2

  • Female patients have more systemic symptoms, while younger and male patients have more neurologic symptoms. 2

Hemodynamic and Hematologic Consequences

  • Hemolysis from the tumor can engage systemic heme oxygenase-1, leading to increased carboxyhemoglobin concentrations and plasmatic hypercoagulability through carboxyhemefibrinogen formation. 7

  • This hypercoagulable state manifests as abnormally large velocity of plasma thrombus growth and strength with reduced vulnerability to lysis on thromboelastography. 7

  • Severe pulmonary hypertension can develop when large tumors obliterate the left atrium and obstruct mitral valve flow, causing backward transmission of elevated left atrial pressure. 8

Clinical Implications of Pathophysiology

  • The pathophysiologic mechanisms collectively determine risk profile and urgency of intervention: mechanical obstruction can cause sudden death, embolic complications cause stroke and organ infarction, and constitutional symptoms indicate active tumor biology. 1

  • Anticoagulation or antiplatelet therapy alone is inadequate because it does not prevent tumor embolization or relieve mechanical obstruction; only surgical excision addresses all three pathophysiologic mechanisms. 1, 5

  • Complete tumor removal with adequate margin of atrial septum is essential because incomplete excision leads to recurrence in 1-5% of sporadic cases (higher in familial Carney complex). 1, 9

References

Guideline

Diagnosis and Management of Left Atrial Mass with Syncope

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Surgical Management of Cardiac Myxoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Acute Ischemic Stroke Caused by Left Atrial Myxoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

A left atrial myxoma complicated with acute myocardial infarction.

Internal medicine (Tokyo, Japan), 1997

Research

Left atrial myxoma presenting as pulmonary embolism: potential role of heme oxygenase-1.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.